The bottom line of CAR-T fungal risk: low incidence, high stakes and the need for individualised antifungal prophylaxis

IF 4.4 3区 医学 Q2 HEMATOLOGY Transplantation and Cellular Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-13 DOI:10.1016/j.jtct.2024.12.013
Gemma K. Reynolds , Monica A. Slavin
{"title":"The bottom line of CAR-T fungal risk: low incidence, high stakes and the need for individualised antifungal prophylaxis","authors":"Gemma K. Reynolds , Monica A. Slavin","doi":"10.1016/j.jtct.2024.12.013","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"31 1","pages":"Pages 4-6"},"PeriodicalIF":4.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666636724008145","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CAR-T真菌风险的底线:低发病率,高风险和个体化抗真菌预防的需要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.00
自引率
15.60%
发文量
1061
审稿时长
51 days
期刊最新文献
QTc Prolongation in Allogeneic Hematopoietic Stem Cell Transplantation: Assessing Cardiac Complications and Survival Outcomes. Incidence, Risk Factors and Outcomes of Sinusoidal Obstruction Syndrome in Patients undergoing Allogeneic Hematopoietic Cell Transplantation with PTCy-based Prophylaxis. Efficacy of Low-Dose Olanzapine for the Prevention of Conditioning Therapy-Induced Nausea and Vomiting in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Gilteritinib for Prevention of Post-Transplant Relapse in Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation: Real Life Data from Two Centers. Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1